Elan Faces Shareholder Suit Over Alzheimer's Drug
Elan Corp. has been slammed with a proposed securities class action alleging the biotechnology giant lied to investors about the results of a clinical trial of a drug it was developing...To view the full article, register now.
Already a subscriber? Click here to view full article